الرئيسية » أرشيف الكاتب: Catherine Skari

أرشيف الكاتب: Catherine Skari

New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019

  Celgene Corporation, Acceleron Pharma, Sangamo Therapeutics & Agios Pharmaceuticals are expected to present new and updated data on the progress of key ongoing therapies for thalassaemia and sickle cell disease (SCD) in the 61st American Society of Hematology Annual Meeting to take place in Orlando, Florida, 7-10 December 2019. ...

أكمل القراءة »

Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA

  The European Medicines Agency’s (EMA) has recently granted marketing authorisation for the medicinal product ”Deferasirox Mylan”, intended for the treatment of chronic iron overload due to blood transfusions in patients with β-thalassaemia major, non-transfusion-dependent thalassaemia syndromes and other anaemias. The manufacturer of this medicinal product is Mylan S.A.S. ”Deferasirox Mylan” will be ...

أكمل القراءة »

High-Level Thalassaemia & Sickle Cell Disease Healthcare Professionals Summit – 1 & 2 November 2019

After the successful Capacity Building Workshop for Patient Organizations & Patients with thalassaemia, TIF will be traveling to Thessaloniki, Greece for a High-Level Thalassaemia & Sickle Cell Disease Healthcare Professionals’ Summit, to be held on 1-2 November 2019. Seeking to inform the healthcare community working in Europe about the optimal ...

أكمل القراءة »

US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV

  The National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation will each invest $100 million over the next four years to speed the development of affordable gene therapies for sickle cell disease (SCD) and the human immunodeficiency virus (HIV) on a global scale. The collaboration between the NIH and the Gates Foundation sets ...

أكمل القراءة »

As survival increases in β-thalassemia, renal complications emerge

  In a scientific paper recently published in Hematology, researchers discussed the most common pathophysiologic and clinical manifestations of renal disease in patients with beta thalassaemia. “In recent years, the life expectancy of patients with thalassaemia has increased, and this has allowed previously unrecognized renal complications to reveal themselves,” said ...

أكمل القراءة »

The future of genome editing in Europe – Bringing together the views of government, industry, patient communities, and civil society’ representatives

  Genome editing is a breakthrough healthcare technology which has the potential to notably change treatment options, largely influence current healthcare models, and impact patients in clinical trials worldwide. The science is advancing rapidly, promising considerable increases in the efficacy and precision of genome editing products with potentially curative treatments ...

أكمل القراءة »